Synagis (palivizumab), AbbVie's respiratory syncytial virus (RSV) prophylactic for use in high-risk infants and children under two years, has been reformulated and is now available as a solution for injection.
Click to search or browse MIMS
The most up-to-date drug information at your fingertips.
- Get the prescribing support you need.
- Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Access the full drug database and quick-reference tables on the go